Clinical Gastroenterology and Hepatology最新文献

{"title":"The Global Rising Tide of Advanced Fibrosis/Cirrhosis.","authors":"Karl Vaz, William Kemp, Ammar Majeed, David Simmons, Stuart K Roberts","doi":"10.1016/j.cgh.2025.06.048","DOIUrl":"10.1016/j.cgh.2025.06.048","url":null,"abstract":"","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":12.0,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data From Nine Countries.","authors":"Zobair M Younossi, James M Paik, Jeffrey V Lazarus, Patrizia Burra, Yuichiro Eguchi, Frank Tacke, Javier Crespo, Cristiane A Villela-Nogueira, Paul N Brennan, Hussain Abdulrahman Al-Omar, Manuel Romero-Gomez, Cyrielle Caussy, Mário Guimarães Pessoa, Kenneth Cusi, Michael Roden, Hirokazu Takahashi, Amalia Gastaldelli, Jörn M Schattenberg, Claudia Pinto Oliveira, Takumi Kawaguchi, Yuko Eguchi, Jerome Boursier, Faisal Abaalkhail, Jeremy W Tomlinson, Alina M Allen, Vincent Wai-Sun Wong, Elisabetta Bugianesi, Philip N Newsome, Jose Luis Calleja, Nicolai Brachowicz, Leire Agirre-Garrido, Douglas Maya-Miles, Habeeb I A Razack, Henry E Mark, Ariana Nader, Sara Battistella, Jennifer Margier, Alessandra Risso, Maria Stepanova, Fatema Nader, Linda Henry, Laurent Castera, Saleh A Alqahtani","doi":"10.1016/j.cgh.2025.09.002","DOIUrl":"10.1016/j.cgh.2025.09.002","url":null,"abstract":"<p><strong>Background & aims: </strong>Although the clinical burden of metabolic dysfunction-associated steatohepatitis (MASH) is well-known, its economic burden is less well-described. We estimated MASH's economic burden in several regions of the world including the United States (U.S.), Germany, Spain, France, Italy, the United Kingdom (UK), Japan, Saudi Arabia, and Brazil over the next 2 decades.</p><p><strong>Methods: </strong>A 1-year cycle Markov model projected MASH progression from 2021 to 2040, incorporating 2020 prevalent cases and annual incident cases (2021-2040). Transition probabilities were derived from the literature, calibrated using national estimates of prevalence rates for type 2 diabetes and obesity, and adjusted against observed incidences of decompensated cirrhosis, hepatocellular carcinoma, and liver transplants. MASH-related direct costs, productivity losses, and quality-of-life were updated annually based on projected disease stage. Future economic burdens were adjusted using country-specific inflation rates from the International Monetary Fund.</p><p><strong>Results: </strong>MASH prevalence is projected to increase (2021-2040): United States (6.71%-7.41%), Germany (4.43%-4.97%), Spain (4.50%-5.38%), France (4.04%-4.50%), Italy (4.58%-5.37%), United Kingdom (4.75%-5.21%), Japan (3.67%-5.02%), Brazil (7.19%-7.52%), and Saudi Arabia (7.39%-7.50%). The prevalence of advanced MASH (F3- compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, and liver transplantations) is expected to increase by ≥20% in all countries. Direct annual medical costs are projected to more than double, increasing from $34.97 to $78.59 billion in the United States, $0.83 to $1.82 billion in Germany, $1.48 to $3.50 billion in Spain, $1.28 to $2.90 billion in France, $1.34 to $3.00 billion in Italy, $2.18 to $5.29 billion in the United Kingdom, $1.20 to $2.33 billion in Japan, $3.41 to $9.81 billion in Brazil, and $1.72 to $3.96 billion in Saudi Arabia. Work productivity losses are projected to more than double in most countries, and health-related quality of life will decline modestly as the burden of advanced disease increases CONCLUSIONS: Without intervention, the clinical, economic, and quality-of-life burden of MASH is projected to increase across most regions of the world. These findings highlight the urgent need for both national and global strategies to reduce the negative impact of MASH on individuals and society.</p>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":12.0,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145032983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fecal Microbiota-based Therapies Compared to Fecal Microbiota Transplantation for Preventing Recurrent C. difficile Infection.","authors":"Larry Nguyen, Paul Feuerstadt, Jessica R Allegretti, Jordan Axelrad","doi":"10.1016/j.cgh.2025.08.029","DOIUrl":"10.1016/j.cgh.2025.08.029","url":null,"abstract":"","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":12.0,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433683/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145032986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Safety of Orodispersible Budesonide for Eosinophilic Esophagitis: A Multicenter Real-World Study.","authors":"Daria Maniero, Matteo Ghisa, Alessandro Bruschi, Greta Lorenzon, Luisa Bertin, Giorgia Giorgini, Emanuele Bendia, Marina Coletta, Roberto Penagini, Pierfrancesco Visaggi, Nicola de Bortoli, Edoardo Vespa, Alberto Barchi, Amir Mari, Emanuele Dilaghi, Bruno Annibale, Paola Iovino, Elvira Di Feo, Marco Caminati, Federico Caldart, Salvatore Russo, Elisa Marabotto, Pasta Andrea, Rosa Lovero, Antonio Pisani, Antonio Di Sabatino, Marco Vincenzo Lenti, Carlo Maria Rossi, Stefania Merli, Davide Giuseppe Ribaldone, Erica Bonazzi, Edoardo Vincenzo Savarino","doi":"10.1016/j.cgh.2025.08.033","DOIUrl":"10.1016/j.cgh.2025.08.033","url":null,"abstract":"<p><strong>Background & aims: </strong>Topical corticosteroids represent one of the effective first-line treatment options for eosinophilic esophagitis (EoE), and therapy with budesonide orodispersible tablets (BOTs) has been recently approved for the treatment of EoE and showed great efficacy in randomized-controlled clinical trials, however real-life data are lacking. Thus, we aimed to evaluate the effectiveness of treatment with BOTs in adult EoE patients in a real-life setting.</p><p><strong>Methods: </strong>In this prospective study, clinical, histologic, endoscopic, and safety measures were assessed. Patients underwent evaluation after the induction period (12 weeks) and up 1 year of treatment with BOTs. Dysphagia Symptom Questionnaires were used for symptoms; the Adult Eosinophilic Esophagitis Quality of Life questionnaire for quality of life; the Endoscopic Reference Score for endoscopic activity; eosinophilic peaks (eosinophils per high-power field) for histologic activity.</p><p><strong>Results: </strong>A total of 233 patients were enrolled and 203 completed the assessments after 12 weeks. Deep histological remission was achieved by 84% of patients, as well as clinical remission, associated with an improvement in quality of life. Eighty-six patients concluded 1 year of treatment, and 78% were still in deep remission, while 15% experienced a loss of histological response at treatment tapering. Primary nonresponders were 8%, and secondary nonresponders were 3%. No serious adverse effects were recorded. Only mild side effects related to drug assumption were reported by 28 (12%) of 233 patients, and the most common were oral symptoms.</p><p><strong>Conclusions: </strong>Our real-world data confirm that BOTs are effective in inducing clinical and histologic remission in most EoE patients. The drug has a good safety profile, with side effects occurring only in a small number of patients.</p>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":12.0,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145032972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world Use of Terlipressin in Cirrhosis and Acute Kidney Injury: Frequent Use Beyond Hepatorenal Syndrome.","authors":"Ann T Ma, Adrià Juanola, Kavish R Patidar, Anna Barone, Simone Incicco, Anand V Kulkarni, Nipun Verma, Christian M Lange, Qing Xie, Carlo Alessandria, Eira Cerda Reyes, Rakhi Maiwall, Jeong Han Kim, Sebastián Marciano, Alberto Queiroz Farias, Claudio Toledo, Silvia Nardelli, Julio D Vorobioff, Juan Pablo Roblero, Thierry Thévenot, Maria Papp, Raoel Maan, Cristina Solé, Jacqueline Cordova-Gallardo, Douglas A Simonetto, Yasser Fouad, Lorenz Balcar, Sarah Raevens, Puria Nabilou, Paolo Caraceni, Manuela Merli, José Presa, Wim Laleman, Aleksander Krag, Tony Bruns, Gustavo Pereira, Angelo Z Mattos, Juan Pablo Arab, Brian Wentworth, Nadia Abdelaaty Abdelkader, Yu Jun Wong, Sung-Eun Kim, Olivier Roux, R Bart Takkenberg, Antonio Galante, Luciana Lofego Goncalves, Nikolaos T Pyrsopoulos, José Luis Pérez Hernández, Sumeet K Asrani, Aldo Torre, Javier Díaz-Ferrer, Eric S Orman, Giovanni Perricone, Adrian Gadano, Vladimir Ivashkin, Eduardo Fassio, Mónica Marino, Victor Vargas, Liane Rabinowich, Pedro Montes, Abdulsemed Mohammed, Enrique Carrera, María Cecilia Cabrera, Marcos Girala, Hrishikesh Samant, Joao Madaleno, W Ray Kim, Carlos Noronha Ferreira, Andrew S Allegretti, Shiv K Sarin, Pere Ginès, Paolo Angeli, Elsa Solà, Salvatore Piano","doi":"10.1016/j.cgh.2025.08.031","DOIUrl":"10.1016/j.cgh.2025.08.031","url":null,"abstract":"<p><strong>Background & aims: </strong>Terlipressin is indicated to treat hepatorenal syndrome (HRS)-acute kidney injury (AKI) but is likely used outside this primary indication in clinical practice. We aimed to investigate real-world practice patterns on the use of terlipressin in AKI in cirrhosis.</p><p><strong>Methods: </strong>International prospective study including patients hospitalized for decompensated cirrhosis. This was a subgroup analysis of patients who received terlipressin to treat AKI. Primary outcome was AKI resolution. Secondary outcomes were respiratory failure and 28-day mortality.</p><p><strong>Results: </strong>Among 1456 patients with AKI, 243 (17%) received terlipressin. Terlipressin was predominantly administered as a continuous infusion (75%). The AKI phenotype was HRS-AKI in 50%, acute tubular necrosis (ATN) in 17%, hypovolemic in 25%, and other in 8%. AKI resolution occurred in 49% of the patients, and was lowest in ATN (29%), followed by HRS-AKI (51%) and hypovolemic (63%). ATN was independently associated with lack of AKI resolution (odds ratio, 2.77; 95% confidence interval, 1.24-6.54; P = .02). De novo respiratory failure occurred in 20% of patients. There were no significant differences in the amount of albumin received nor acute-on-chronic liver failure grade between those who did and did not develop respiratory failure. The presence of pneumonia independently predicted respiratory failure (odds ratio, 7.80; 95% confidence interval, 2.43-26.95; P < .001). Mortality rate at 28 days was 36%; ATN and hospital-acquired AKI independently predicted 28-day mortality.</p><p><strong>Conclusions: </strong>Terlipressin is often used for treatment of AKI outside its primary indication of HRS-AKI. Compared with patients with HRS-AKI, response to terlipressin is significantly lower in patients with ATN, in whom the risks may outweigh the benefits. Respiratory failure is common but does not seem to be driven by the amount of albumin received nor acute-on-chronic liver failure grade.</p>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":12.0,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145032929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infliximab and Ustekinumab Clearance Better Predict Endoscopic Outcomes Than Trough Concentrations in Crohn's Disease.","authors":"Zhigang Wang, Yannick Hoffert, Wei Zhang, Wannee Kantasiripitak, Bram Verstockt, João Sabino, Marc Ferrante, Paul Declerck, Geert D'Haens, David Laharie, Séverine Vermeire, Erwin Dreesen","doi":"10.1016/j.cgh.2025.08.030","DOIUrl":"10.1016/j.cgh.2025.08.030","url":null,"abstract":"<p><strong>Background & aims: </strong>Infliximab and ustekinumab clearance have been suggested as predictors of disease activity in patients with inflammatory bowel diseases. We aimed to investigate the benefits of clearance monitoring for predicting endoscopic outcomes in patients with Crohn's disease (CD).</p><p><strong>Methods: </strong>Data from patients with moderate-to-severe CD starting infliximab (n = 108) and ustekinumab (n = 80) therapy were repurposed. Endoscopic remission (CD Endoscopic Index of Severity <3) was assessed at week (w)12 and w54 of infliximab therapy. Endoscopic response (>50% reduction in Simple Endoscopic Score for CD) was assessed at w24 of ustekinumab therapy. We performed Bayesian forecasting to estimate time-varying mAb clearance using drug concentrations, covariates, and in-house developed population pharmacokinetics models.</p><p><strong>Results: </strong>Patients achieving endoscopic remission at w12 had significantly lower infliximab clearance and higher infliximab serum trough concentrations (C_trough) at w2 of standard 5 mg/kg infliximab induction therapy, than patients without endoscopic remission (P < .05). During infliximab maintenance therapy (with eventual dose optimizations), patients achieving endoscopic remission at w54 had significantly lower infliximab clearance (P < .001) but not higher infliximab C_trough (P = .92) than those without remission. Moreover, infliximab clearance during maintenance had similar discriminative ability as fecal calprotectin (area under the receiver operating characteristics curve 0.63; 95% confidence interval, 0.56-0.69 vs 0.67; 95% confidence interval, 0.61-0.73, respectively). Ustekinumab clearance, but not C_trough, was significantly different between endoscopic responders and nonresponders during standard ustekinumab induction and maintenance therapy (P < .05).</p><p><strong>Conclusions: </strong>Although C_trough loses its ability to predict treatment response when doses are optimized or not administered by bodyweight, infliximab and ustekinumab clearance remains a reliable predictor for endoscopic outcomes.</p>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":12.0,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Socioeconomic Disparity and Risk of Irritable Bowel Syndrome: A Cohort Study With Mediation Analysis.","authors":"Yesheng Zhou, Si Liu, Qian Zhang, Shutian Zhang, Shengtao Zhu, Shanshan Wu","doi":"10.1016/j.cgh.2025.08.034","DOIUrl":"10.1016/j.cgh.2025.08.034","url":null,"abstract":"<p><strong>Background & aims: </strong>The study sought to investigate the association between socioeconomic status (SES) and risk of incident irritable bowel syndrome (IBS), and the mediating role of lifestyle factors.</p><p><strong>Methods: </strong>Participants free of IBS at recruitment were included in this retrospective analysis of a prospectively collected cohort (N = 353,790). SES was assessed through household income, education, and employment status, with different patterns identified through latent class analysis. Healthy lifestyle score was calculated including never smoking, moderate alcohol consumption, healthy diet, regular physical activity, normal body mass index, and healthy sleep duration. The primary endpoint was incident IBS. A Cox proportional hazards model with sequential mediation analysis was used to estimate the association and mediation effect.</p><p><strong>Results: </strong>During a median follow-up of 14.5 years, 7240 (2.1%) incident IBS cases were identified. Overall, 94,660 (26.7%), 186,317 (52.7%), and 72,813 (20.6%) participants were classified into low, medium, and high SES patterns, respectively. A high SES pattern was associated with lower IBS risk vs a low SES pattern (hazard ratio, 0.61; 95% confidence interval, 0.57-0.66), with 10.2% of effect mediated by a healthy lifestyle score. Similar findings were observed for SES scores. Regarding individual SES items, higher household income and education and employed status were linked to 8%-32% lower IBS risk, with 5.6%-20.8% of mediation proportions. Notably, individuals with high SES pattern and healthy lifestyle score of 5 or 6 had a 55% (hazard ratio, 0.45; 95% confidence interval, 0.39-0.51) reduced IBS risk vs those with a low SES pattern and healthy lifestyle score of 0-2.</p><p><strong>Conclusions: </strong>Higher SES is associated with reduced risk of incident IBS with mediation effect of healthy lifestyle factors. Interventions targeting both SES inequalities and lifestyle improvements may help reduce IBS burden.</p>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":12.0,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing for Disparities in Diagnostic Delay Among Patients With Eosinophilic Esophagitis.","authors":"Walker D Redd, Cary C Cotton, Trevor S Barlowe, Craig C Reed, Evan S Dellon","doi":"10.1016/j.cgh.2025.08.032","DOIUrl":"10.1016/j.cgh.2025.08.032","url":null,"abstract":"","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":12.0,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12426945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145022949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Geodemographic Trends in Private Equity Acquisitions of U.S. Gastroenterology Practices: An Analysis of Transactions From 2013 to 2023.","authors":"Todd A Brenner, Michael Liu, Victoria Bartlett, Iman Boston, Rishi K Wadhera, Tyler M Berzin","doi":"10.1016/j.cgh.2025.08.035","DOIUrl":"10.1016/j.cgh.2025.08.035","url":null,"abstract":"","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":12.0,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145022917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biopsychosocial and Environmental Factors That Impact Brain-Gut-Microbiome Interactions in Obesity.","authors":"Riya Sood, Lisa A Kilpatrick, Laurie A Keefer, Arpana Church","doi":"10.1016/j.cgh.2025.07.045","DOIUrl":"10.1016/j.cgh.2025.07.045","url":null,"abstract":"<p><p>Despite significant advances in the understanding of the pathogenesis of obesity and influencing factors, its prevalence continues to increase at an alarming rate. Social determinants of health (SDOH) encompass a broad range of psychosocial and environmental factors, including economic stability, education, access to health care, social support, isolation, neighborhood disadvantage, discrimination, early life adversity, and stress, all of which have been recognized to significantly increase the risk of obesity. This review aims to elucidate the intricate relationship between SDOH and biological mechanisms related to the brain-gut-microbiome (BGM) system that lead to altered eating behaviors and obesity. We conducted a systematic review of the current literature to discuss how SDOH contribute to the development, progression, and management of obesity; and on the BGM mechanisms involved in the influence of SDOH on obesity. The BGM mediates the relationship between SDOH and obesity via orexogenic peptides, inflammatory markers, and neuroactive metabolites that affect ingestion-related decision-making and mood. Dysregulations in the BGM system as a result of environmental stressors can contribute to physiological changes in the gut microbial composition, hypothalamic-pituitary-adrenal axis signaling, and structural changes in the reward network, collectively leading to an increased drive toward the consumption of calorie-dense foods. By recognizing and addressing the impact of various SDOH on BGM interactions, health care providers can provide a more equitable and personalized approach that will enhance treatment adherence and the quality of life for individuals with obesity.</p>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":12.0,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}